Hepatitis C Antibodies among
Blood Donors, Senegal, 2001
To the Editor: Prevalence of chronic hepatitis C virus (HCV) among blood donors has been assessed in a few West African countries; most recent estimates range from 1.1% to 6.7% (1) (2) (3) (4) . A recent meta-analysis of studies, including a confirmation test, yielded an average prevalence of HCV infection of 3.0% (5) . Until 2001, no systematic screening of HCV infection occurred among blood donors in Senegal, and blood donation legislation is still pending. We report an assessment of the proportion of blood donors from the Hôpital Principal de Dakar who had HCV antibodies in 2001.
Blood donors were all volunteers, recruited independently from the hospitalized patients and registered in a local donors association. We screened for risk factors for bloodborne infections in potential donors through a clinical examination and a confidential questionnaire. Persons with a history of jaundice or a risk behavior were excluded. (6) . Conversely, high HCV prevalence was found in groups at risk: antibodies were present in 12 of 15 hemodialysis patients, and HCV RNA was found in 6 of the 12 HVC antibody-positive patients (genotype 2ac, the same as in our study); 7% of a cohort of 58 HIV-1 patients receiving highly active antiretroviral therapy had a positive HCV serologic result (7, 8) .
In the urban setting of Dakar, HCV infection seems still to be confined to groups at risk. The contribution of HCV to chronic liver diseases has not been yet demonstrated. Approximately 15,000 blood donations are annually made in Dakar. A systematic screening of HCV antibodies in blood donors could prevent, on average, 120 bloodborne HCV infections each year. Given these data and the price of EIA and LIA, the screening cost per HCVpositive sample identified, and infection subsequently averted, is approximately 200,300 CFA (U.S.$305). This estimate is low since it includes only the marginal cost of the reagent kits. This screening cost could be reduced by discarding blood units that test positive after only one enzyme-linked immunosorbent assay (156,000 CFA or U.S.$237), at the price of nearly 3% of blood units wrongly discarded. France has demonstrated that this strategy has the best cost-effectiveness ratio, as long as the prevalence remains below 8% (9) . This cost compares favorably with the cost per HIV infection averted through improvement of blood safety (range U.S.$20-U.S.$1,000), assessed in some highly HIV-prevalent southern African countries (Tanzania, Zambia, Zimbabwe) (10) . The HCV-positive discarded blood units will be added to the blood units testing positive for hepatitis B surface (13%), HIV, and HTLV, which accounted for nearly one third of all donations in 2001. These findings argue in favor of maintaining a roster of regular, seronegative donors to save numbers of blood units.
